ArticleACS omega2025
Dose-Dependent Scavenging of Methylglyoxal by Naringenin in Diabetic Mice.
Article in ACS omega, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Mitigating effect of naringenin on potassium bromate-induced nephrotoxicity in vivo.Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
- Glycolytic lactylation modulates cell death decisions in diabetic kidney disease: Metabolic‑epigenetic interplay between ferroptosis and autophagy in fibrotic remodeling (Review).International journal of molecular medicine · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Methylglyoxal (MGO) has driven interest as a major precursor of advanced glycation end products due to it being closely implicated in the pathogenesis of diabetic kidney disease (DKD). Therefore, it is critical for seeking active scavenger-targeted MGO to mitigate the development of DKD. Previous studies demonstrated that naringenin (Nar) has a remarkable therapeutic effect on DKD. However, whether Nar could scavenge MGO in diabetic mice remains virtually unknown. This work aims to investigate the effect and mechanism of scavenging MGO by Nar in diabetic mice. Liquid chromatography coupled to tandem mass spectrometry (LC-MS/MS) was applied for investigating the scavenging capacity and mechanism of Nar on MGO in diabetic mice. The results indicated that Nar could significantly scavenge MGO in diabetic mice based on the formation of mono-MGO-Nar. In addition, two mono-MGO-Nar nanoparticles were purified, and their structures were deduced as 3-MGO-Nar using LC-MS/MS and NMR spectroscopic analyses. Furthermore, the dose-dependent scavenge effect of Nar on MGO in diabetic mice was elucidated by quantifying mono-MGO-Nar in urine and feces using LC-MS/MS. In summary, our results first demonstrated that targeting the MGO burden may be the new mechanism of Nar combating DKD.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.